AXSM · Healthcare · $9.5B
$182.61-0.96%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 327 Biotechnology peers
Quarterly Revenue Growth
“지난주 FDA가 AUVELITY를 알츠하이머 환자의 흥분·공격 증상 치료제로 추가 승인했어요.”
In the company's words · 2026 1분기 earnings call